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of the inflammatory response and healing process. Serum 
amyloid A (SAA) is one of the most striking AP reactants 
that can rapidly increase up to a 1,000-fold or more in 
plasma concentration with appropriate stimuli (1, 2). SAA 
is found in AP plasma mainly as an apolipoprotein of HDL 
(3) and is produced largely by the liver in response to pro-
inflammatory cytokines, including IL-1, IL-6, and TNF, 
which are released from macrophages exposed to inflam-
matory agents (4, 5). Following removal of inflammatory 
stimulants, SAA is cleared rapidly over 72 h, suggesting 
that SAA clearance/catabolism may be important to the 
homeostasis of inflammatory events (1).
In chronic inflammatory diseases, such as rheumatoid 
arthritis, atherosclerosis, Crohn’s disease, obesity, and dia-
betes, plasma concentrations of SAA are also elevated and 
are maintained at more moderate concentrations. SAA 
levels have been linked to atherosclerotic cardiovascular 
disease (6). However, the physiological functions of SAA 
during chronic or AP inflammation are poorly understood. 
Human SAA has been implicated in several potentially 
important functions, such as monocyte chemotaxis, endothe-
lial dysfunction, cytokine induction, subendothelial lipopro-
tein retention, and induction of matrix metalloproteinases 
(7–11). However, these reports were largely based on data 
obtained using a commercially available recombinant 
human SAA, a molecule that differs significantly from 
naturally occurring SAA in containing an N-terminal 
methionine and amino acid sequences of both human 
SAA1 and SAA2. Recently, it has been suggested that this 
recombinant SAA exerts effects not shown by native SAA 
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Brook, NY). The two genes are located approximately 9 kb apart, 
but in opposite orientation, on chromosome 7. For the SAA1.1KO 
mouse, a 15.9 kb region was used to construct the targeting vec-
tor. The region was designed such that the short homology arm 
extended 2.1 kb and the long homology arm 8.5 kb, 5′ and 3′ 
respectively, of a loxP/FRT floxed neo cassette. This cassette re-
placed 5.3 kb of the SAA1.1 gene including exons 2-4 and the 
translation start codon. For the SAA2.1KO mouse, a 12.5 kb re-
gion was used to construct the targeting vector. The short homol-
ogy arm extended 2.0 kb and the long homology arm 8.1 kb, 
3′ and 5′ respectively, of a neo cassette that replaced 2.4 kb of the 
SAA2.1 gene including exons 2-4 and the start codon. Cholesteryl 
ester transfer protein (CETP) transgenic (CETPtg) mice (B6.
CBA-Tg(CETP)5203Tall/J) were obtained from the Jackson Lab-
oratory. CETPtg mice were crossed with scavenger receptor class 
B type I (SR-BI)KO mice (generously provided by Dr. M. F. Lin-
ton) to generate CETPtg/SR-BIKO mice. All mice were on a 
C57BL/6 background and 8–12 weeks of age.
Mice were maintained in a pathogen-free facility under equal 
light-dark cycles with free access to water and food. An AP re-
sponse was elicited by intraperitoneal injection of lipopolysac-
charide (LPS) (Escherichia coli 0111:B4; Sigma Chemical Co.) at a 
dose indicated for the individual experiments. Plasma and HDL 
lipids were measured with enzymatic kits (Wako Chemicals). All 
procedures were carried out in accordance with United States 
Public Health Service policy and approved by the Veterans Af-
fairs Medical Center Institutional Animal Care and Use Commit-
tee (Assurance number A3506-01).
HDL isolation, characterization, and radiolabeling
Plasma from 15–25 mice (equal numbers of male and female 
mice) was pooled for HDL isolation by sequential density gradient 
ultracentrifugation (d = 1.063–1.21 g/ml) (3). For the prepara-
tion of HDL from AP mice, mice were injected with LPS (6 g/g) 
24 h before plasma collection. HDL was dialyzed against 150 mM 
NaCl and 0.01% EDTA, sterile filtered, and stored under argon 
gas at 4°C. HDL protein concentrations were determined by the 
method of Lowry et al. (34). HDL was characterized by SDS-PAGE 
(4–20% polyacrylamide SDS gels) and gradient gel electrophore-
sis (4–20% nondenaturing polyacrylamide gels on which HDL 
was electrophoresed for 3.5 h at 200 V, 4°C). HDL apolipoproteins 
were radiolabeled with 125I following the method of Bilheimer, 
Eisenberg, and Levy (35). HDL lipids were measured with enzy-
matic kits (439-17501, cholesterol; 461-08992 and 461-09092, 
TGs; 435-35801, free cholesterol (FC); and 433-36201, phospho-
lipids (PLs); Wako Chemicals) and average values of three differ-
ent HDL preparations are reported.
Electrofocusing
Aliquots (7 l) of plasma from mice injected with LPS (4 g/g) 
were subjected to electrofocusing as described, using an Ampho-
line gradient consisting of 20% (v/v) ampholines (pH 3–10), 
40% (v/v) ampholines (pH 4–6.5), and 40% (v/v) ampholines 
(pH 7–9) (Pharmacia LKB Biotechnology, Inc.). Electrofocused 
samples were subjected to immunochemical analysis of SAA, as 
previously described (36).
Lipoprotein cholesterol distributions
Lipoprotein classes were separated by gel filtration chroma-
tography and their cholesterol content determined as described 
previously (37). Briefly, plasma aliquots were diluted to 0.5 g 
total cholesterol (TC) per microliter with 0.9% NaCl and 0.05% 
EDTA/NaN3, and centrifuged to remove any particulate debris. 
Aliquots (40 l) of the diluted samples were injected into a Supe-
rose 6 10/300 (GE Healthcare Life Sciences) chromatography 
(12, 13). Native SAA has been shown to alter both the pro-
tein and lipid composition of AP-HDL (14) and also to 
influence HDL remodeling (15) and cholesterol efflux 
from cells (16). Although several studies have reported 
that inflammation impedes reverse cholesterol transport 
to the liver (17–19), we have recently shown that impair-
ment of reverse cholesterol transport in mice during in-
flammation does not depend on SAA (20). An absence of 
SAA also did not affect atherosclerosis in an apoE-deficient 
mouse model (21). However, SAA was shown to enhance 
abdominal aortic aneurysm in an angII-dependent ab-
dominal aortic aneurysm mouse model (22).
The SAA gene family is highly conserved in mammals, 
comprising four closely related genes. Human SAA1 and 
SAA2 encode for the two major AP proteins, SAA1 and 
SAA2 (designated SAA1.1 and SAA2.1, respectively, in mice). 
The SAA1 and SAA2 genes are present in a gene cluster on 
human chromosome 11p15.1 and are coordinately in-
duced during inflammation (23). SAA3 is a pseudo-gene 
in humans (24), but is expressed in mice. SAA4 is constitu-
tively expressed and is present at low levels in both normal 
and AP plasma (1). Mouse SAA1.1 and SAA2.1 share 91% 
amino acid sequence identity and, like their human ho-
mologs, are highly induced during inflammation.
SAA has been shown to be a precursor of amyloid A pro-
tein, the main component of reactive systemic amyloid that 
may be deposited in organs as a result of chronic inflamma-
tion (25, 26). Reactive systemic amyloid A amyloidosis can 
complicate chronic inflammatory disorders that are associ-
ated with a sustained AP response. Interestingly, although 
murine SAA1.1 and SAA2.1 are produced at similar rates in 
the liver in response to cytokines, only SAA1.1 is deposited 
into amyloid fibrils in mice (27). Similarly, SAA1 is the pre-
dominant isoform deposited in amyloid fibrils in humans 
(28). With regard to other possible functional differences 
between the two isoforms, murine SAA2.1, but not SAA1.1, 
has been reported to suppress ACAT and to stimulate cho-
lesterol ester hydrolase (CEH), functions that both might 
promote cholesterol efflux (29). Together, these findings 
demonstrate that SAA isoforms can have different meta-
bolic functions and fates.
Several studies have investigated SAA catabolism in 
mice (30, 31) and in monkeys (32, 33). Because SAA1.1 
and SAA2.1 are present in the same lipoprotein fraction in 
plasma and have a similar molecular mass, as well as amino 
acid sequence, it has been difficult to determine plasma 
degradation rates of these individual isoforms in naturally 
occurring HDL. In this study, we have used mice deficient 
in either SAA1.1 or SAA2.1 to investigate SAA isoform 
clearance rates and the effects of these SAA isoforms on 
HDL structure and composition, as well as their effects on 
HDL apolipoprotein clearance.
MATERIALS AND METHODS
Generation of SAA1.1KO and SAA2.1KO mice
Targeted deletion of the SAA1.1 gene and the SAA2.1 gene 
was performed by InGenious Targeting Laboratory, Inc. (Stony 
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band for volume of plasma loaded on the gel. Clearance rate 
determinations were performed for each of the five animals per 
group.
Analysis of plasma apolipoprotein clearance curves was per-
formed using GraphPad PRISM software, which was used to fit 
the two-phase exponential clearance curves for each mouse. Pla-
teau values were constrained to zero. The biphasic fit generated 
rate constants for the fast and slow pools and their relative pool 
sizes, which were used to calculate weighted average fractional 
clearance rates (FCRs) for the different apolipoproteins in the 
plasma for each mouse (39). Mean FCR values for each experi-
mental group were calculated from the individual FCR values 
determined in five mice.
Statistical analysis
Data are presented as mean ± SE. Statistical comparisons for 
Table 1, Fig. 2, and supplementary Fig. 2 were based on one- or 
two-way ANOVA with observations weighted based on group vari-
ances. Statistical comparisons for Table 2 and related figures 
were based on unpaired t-tests (or one-way ANOVA) and paired 
t-tests. Benjamini-Hochberg multiplicity adjustments were pur-
sued as appropriate for post hoc tests. Version 9.3 of SAS (SAS 
Institute, Cary, NC) was used for statistical comparisons. P val-
ues less than 0.05 are considered statistically significant and de-
noted in tables or figures with a single asterisk; P values less 
than 0.01 and 0.001 are denoted with two and three asterisks, 
respectively.
RESULTS
Expression of SAA isoforms in isoform-specific KO mice
The two major murine AP SAAs, SAA1.1 and SAA2.1, 
have almost identical sequences and the proteins share 
91% amino acid identity. SAA1.1KO and SAA2.1KO mice 
were generated as described in the Materials and Methods 
and in supplementary Fig. 1A, B. The deletion of the indi-
vidual SAA isoforms was confirmed by isoelectric focusing 
of plasma from LPS-injected isoform-specific mice lacking 
either SAA1.1 or SAA2.1 (Fig. 1), and was consistent with 
the lower levels of total SAA mRNA detected in the two 
isoform-specific KO mice compared with WT mice (sup-
plementary Fig. 2). SAA was undetectable in plasma from 
nonacute control mice (data not shown). Both SAA iso-
forms are highly induced by LPS and the relative levels of 
protein and mRNA suggest that induction may be lower 
for SAA1.1 than for SAA2.1.
column by means of an autosampler set at 4°C (Agilent Tech-
nologies; G1329A) and the lipoprotein classes separated at a flow 
rate of 0.4 ml/min. The effluent was mixed with TC enzymatic 
reagent (Pointe Scientific) to allow for cholesterol determination. 
The absorbance of the reaction mixture at 500 nm was integrated 
using Agilent OpenLAB Software Suite (Agilent Technologies) 
and normalized to the TC concentration of the sample.
Real-time PCR
Total RNA was isolated from mouse liver using TRIzol reagent 
(Invitrogen) according to manufacturer’s protocol. RNA sam-
ples were treated with TURBO DNA-free (Ambion) two times for 
30 min at 37°C. RNA (1 g) was reverse transcribed into cDNA 
using a high capacity cDNA reverse transcription kit (Applied 
Biosystems). After 4-fold dilution, 5 l was used as a template for 
quantitative real-time PCR. Amplification was done for 40 cycles 
using Power SYBR Green PCR Master Mix kit (Applied Biosys-
tems). Quantification was performed in duplicate using the stan-
dard curve method and normalized to 18S. The primers used for 
various genes are shown in supplementary Table 1.
Cellular cholesterol efflux determination
Cellular cholesterol efflux experiments in ABCG1-inducible 
BHK cells were carried out essentially as described (38). Cells 
(70% confluent) in 12-well plates were labeled with 0.2 Ci/ml 
[3H]cholesterol (35–50 Ci/mmol; Amersham Biosciences) in 
complete DMEM medium for 48 h. Cells were then washed three 
times with PBS containing 1 mg/ml BSA (PBS-BSA) and equili-
brated overnight in DMEM containing 0.2% fatty acid-free BSA 
(DMEM-BSA) during which time ABCG1 expression was induced 
with 10 nM mifepristone. Control cells received no mifepristone. 
Following two additional washes with PBS-BSA, cells were incu-
bated for 5 h at 37°C in DMEM-BSA with or without WT HDL, 
SAA1.1KO HDL, SAA2.1KO HDL, or SAAKO HDL, as indicated. 
Following incubation, the medium was collected and centrifuged 
to remove detached cells. Adherent cells were washed twice with 
PBS-BSA at 4°C and twice with PBS. Radioactivity in the media 
was measured in a Packard  liquid scintillation counter. Cellular 
lipid was extracted with hexane/isopropyl alcohol (3:2 v/v) for 
30 min at room temperature and counted for radioactivity. Ef-
flux of cellular [3H]cholesterol to media was expressed as the 
percentage of total radioactivity in media and cells. ABCG1-
specific values were calculated as the difference between the 
efflux values in mifepristone-treated and control cells.
HDL clearance and apolipoprotein turnover studies
HDL clearance studies were performed essentially as described 
(14) by injecting normal or AP mice (1 g/g LPS) with 125I-labeled 
autologous or nonautologous HDL, as set out in figure legends. 
Mice were injected via the tail vein with 10 g 125I-HDL diluted in 
100 l saline. Recipient mice were fasted throughout the study, 
but had free access to water. Blood samples (50 l aliquots) 
were obtained via retro-orbital bleeds at the indicated times, and 
plasma samples, now containing the radiolabeled HDL, were 
counted in a  counter (Packard Cobra II auto ). Plasma decay 
curves were generated by expressing the radioactivity at each 
time point as a percentage of the radioactivity determined 3 min 
after tracer injection. In experiments to determine the clearance 
rates of individual apolipoproteins, aliquots of plasma containing 
equal radioactivity at the different time points were first sub-
jected to SDS-PAGE and the stained and dried gels were then 
subjected to autoradiography to identify the specific apolipopro-
tein bands. Apolipoprotein bands of interest were then excised 
and counted in a  counter. Values of each sample were deter-
mined by correcting the radioactivity associated with each excised 
Fig. 1. Plasma SAA isoforms. Plasma was collected from WT, 
SAA1.1KO, and SAA2.1KO mice 24 h after administration of LPS 
(4 g/g). The figure is from a representative experiment in which 
plasma aliquots (7 l) were subjected to electrofocusing as set out 
in the Materials and Methods followed by blotting for SAA (rabbit 
anti-mouse SAA antisera, De Beer laboratory). Each lane repre-
sents plasma from a single mouse.
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between genotype and LPS effect. We previously pub-
lished that an LPS-induced AP response significantly in-
creased plasma PL levels in SAAKO mice (14). This was 
not observed in mice lacking only one SAA isoform, and 
plasma PL was actually reduced in male LPS-injected 
SAA2.1KO mice (P < 0.001). In summary, plasma lipids 
were relatively similar in WT, SAA1.1KO, and SAA2.1KO 
mice under normal conditions. In response to LPS, plasma 
lipids underwent significant changes, most prominently, 
decreases in HDL cholesterol in all three genotypes and 
significant increases in plasma TGs in male mice only.
The impact of SAA isoforms on plasma lipoprotein 
distribution
The potential impact of the SAA isoforms on plasma 
lipoprotein profiles in the AP was analyzed by fast pro-
tein liquid chromatography. As shown in Supplementary 
Fig. 3A, B, in both male and female mice, overall lipopro-
tein cholesterol profiles of the three different genotypes 
were similar with respect to both the size of the different 
lipoprotein fractions (VLDL, LDL, and HDL) as well as 
their cholesterol levels.
Characterization of AP-HDL from SAA1.1KO and 
SAA2.1KO mice
HDL (density, 1.063–1.21 g/ml) was isolated by sequen-
tial ultracentrifugation from the plasma of SAA1.1KO, 
SAA2.1KO, and control WT mice, obtained 24 h after the 
Impact of SAA1.1 or SAA2.1 on plasma lipid levels
The impact of an AP response on the plasma lipid levels 
of WT, SAA1.1KO, and SAA2.1KO mice is shown in Fig. 2. 
A robust AP response was elicited by administering LPS 
(4 g/g body weight), whereas control mice received sa-
line. The plasma lipid levels of WT mice treated similarly 
are shown for comparison. Consistent with our previ-
ously published report on SAAKO mice (14), plasma TC 
was modestly, but significantly, increased in female WT, 
SAA1.1KO, and SAA2.1KO mice after LPS injection. In 
contrast, in male WT, SAA1.1KO, and SAA2.1KO mice, 
plasma TC values were decreased significantly by LPS ad-
ministration and did not exhibit the elevated TC previ-
ously observed in LPS-injected SAAKO mice (14); with 
respect to the different groups, no effect of genotype on 
TC was observed and no interaction between genotype 
and LPS effect was evident. In contrast to plasma TC, HDL 
cholesterol was reduced following LPS administration in 
both female (P < 0.01) and male (P < 0.001) WT and single 
KO mice, in agreement with data published for other 
mammals (40–43). There were no effects of genotype on 
HDL cholesterol and no interaction between genotype 
and LPS effect.
Previous reports (44, 45) have indicated elevated plasma 
TG levels in mice during the AP. We observed increased 
TG levels during the AP in male WT, SAA1.1KO, and 
SAA2.1KO mice (P < 0.001), but not in female mice. There 
were no effects of genotype on TG levels and no interactions 
Fig. 2. Plasma lipids of WT, SAA1.1KO, and SAA2.1KO mice. Plasma was collected from individual male 
and female WT, SAA1.1KO, and SAA2.1KO mice 24 h after intraperitoneal administration of saline or  
4 g/g LPS for the determination of plasma lipid concentrations. TC, HDL cholesterol, PLs, and TGs were 
determined enzymatically with commercial kits (Wako Chemicals). Values represent the mean ± SEM. *P < 
0.05, **P < 0.01, ***P < 0.001 saline versus LPS for each group. In male mice significant differences in 
plasma PL between genotypes are also indicated; *P < 0.05; n = 5.
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LPS, SAAKO HDL shows a significant decrease in protein 
and increase in PL content compared with WT HDL (14). 
This change occurred only in SAAKO HDL and not in WT 
HDL. With respect to cholesterol content, the AP response 
significantly increased the FC content of HDL (P < 0.001) 
and decreased the cholesterol ester (CE) content (P < 
0.001) in each genotype, as previously shown in SAAKO 
mice (14). However, no significant genotype effect in de-
termining FC and CE contents was evident. FC/CE ratios 
in AP-HDLs also showed no significant differences be-
tween genotypes, suggesting ACAT activity and choles-
terol esterification of HDL cholesterol were unaltered.
Impact of SAA isoforms on HDL function in cellular 
cholesterol efflux
ABCG1 is known to utilize HDL as its preferred accep-
tor (46). Using the ABCG1-inducible BHK in vitro model 
system (46, 47), we previously showed that AP-HDL can 
enhance cellular cholesterol efflux mediated by ABCG1 
and that it was likely the PL enrichment of AP- HDL and 
not the presence of SAA that was responsible for the al-
tered efflux. In the present study, we utilized the same 
in vitro system to compare the influence of SAA1.1 and 
SAA2.1 on ABCG1-mediated efflux to AP-HDLs prepared 
from WT, SAA1.1KO, SAA2.1KO, and SAAKO mice. As 
shown in Fig. 4, each of the AP-HDLs mediated both 
ABCG1-dependent and -independent efflux. ABCG1-
dependent efflux was approximately 40% higher for the 
SAA single and double KO AP-HDLs than for WT AP-HDL. 
However, no significant differences in efflux were seen be-
tween ABCG1-dependent efflux to SAA1.1KO AP-HDL 
and SAA2.1KO AP-HDL. There was also no significant dif-
ference in ABCG1-dependant efflux between SAAKO AP-
HDL and either SAA1.1KO or SAA2.1KO AP-HDLs. 
Similar to ABCG1-dependent efflux, nonspecific efflux 
and total efflux values were, in all cases, significantly 
greater for the SAA-depleted AP-HDLs than for WT AP-
HDL, although the differences between the WT AP-HDL 
and the SAA-depleted HDLs were not as great as for 
ABCG1-dependent efflux.
Plasma clearance of HDL apolipoproteins in normal and 
AP mice
To evaluate the rates of plasma clearance of individual 
HDL apolipoproteins in normal mice and AP mice, HDL 
was isolated from WT mice under normal healthy condi-
tions (N-HDL) or mice in the AP 24 h following injection 
with LPS (AP-HDL). HDLs were radio-iodinated and the 
clearance of 125I-N-HDL and 125I-AP-HDL apolipoproteins 
were compared in control normal mice or AP mice. To 
specifically compare the clearance rates of individual apo-
lipoproteins, plasma aliquots were collected at the indi-
cated times after injection of 125I-HDL and subjected to 
SDS-PAGE to separate the different apolipoproteins. Ra-
dioactivity in each band was determined and expressed as 
a percentage of the corresponding radioactivity detected 
at 3 min. Among the apolipoproteins of AP-HDL, SAA 
(FCR = 0.22 ± 0.03/h) was cleared at a significantly faster 
rate in AP mice than apoA-I (FCR = 0.062 ± 0.006/h) (Fig. 5; 
injection of saline [normal HDL (N-HDL)] or 6 g/g LPS 
(AP-HDL). HDL apolipoprotein composition was analyzed 
in a Coomassie-stained SDS gel and showed the expected 
presence of SAA only in AP-HDLs (Fig. 3A). AP-HDL from 
WT mice was shown on a separate gel for comparison to 
the HDLs from SAA1.1KO and SAA2.1KO mice. SAA was 
present at similar levels in each of the AP-HDLs from sin-
gle KO mice, where it was the second most abundant HDL 
apolipoprotein. The normal low level of apoE was also in-
creased in the AP-HDLs from both single KO mice, as was 
also reported for AP-HDL from WT and SAAKO mice (14). 
As previously shown, AP-HDL from WT mice migrated on 
nondenaturing gradient gel electrophoresis as larger-sized 
particles compared with N-HDL (14) (Fig. 3B). The AP-
HDLs from LPS-injected SAA1.1KO and SAA2.1KO mice 
migrated similarly to the AP-HDL from WT mice with an 
apparent increased Stokes radius, and no size difference 
was evident between the two SAAKO genotypes. We have 
shown that AP-HDL from SAAKO mice also migrates simi-
larly to WT AP-HDL (14). Thus, the absence of one or 
both SAA isoforms did not substantially affect the appar-
ent size of AP-HDL.
The protein/lipid composition of the different AP-HDLs 
is shown in Table 1. No significant differences between 
genotypes were observed regarding total protein, TG, and 
PL composition, either in LPS-treated or LPS-untreated 
mice. The AP-HDLs showed higher PL content for all geno-
types, but this difference did not reach significance. These 
findings differ from our earlier finding that in response to 
Fig. 3. Characterization of HDL. HDL (d = 1.063–1.21) was iso-
lated by sequential ultracentrifugation from pooled plasma from 
15–20 WT, SAA1.1KO, and SAA2.1KO mice 24 h after the intraperi-
toneal injection of saline or LPS (6 g/g). A: HDL apolipoproteins 
were separated by SDS-PAGE on a 4–20% acrylamide gel. B: HDL 
size was determined by nondenaturing gel electrophoresis using a 
4–20% acrylamide gel. Protein loading was 5 g HDL per lane and 
visualization was by Coomassie staining. Gels shown are representa-
tive of three separate lipoprotein preparations.
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section A). The clearance rates of both apoA-I and apoA-II 
in N-HDL were similar to their respective clearance rates 
in AP-HDL. These results indicated that, in the AP, neither 
the presence of SAA nor other possible changes in AP-
HDL exert a significant effect on the clearance of apoA-I 
or apoA-II, the two major apolipoproteins on N-HDL.
Plasma clearance of SAA isoforms
The SAA isoform-specific KO mice were used to investi-
gate and compare the clearance rates of SAA1.1 and SAA 
2.1 present in AP-HDL. AP-HDLs containing either 
SAA1.1 or SAA2.1 were prepared from AP SAA2.1KO and 
SAA1.1KO mice, respectively. Plasma clearance rates of 
the two SAA isoforms, as well as apoA-I and apoA-II, were 
then determined in syngeneic mice made AP by LPS injec-
tion. Thus SAA1.1KO mice received HDL prepared from 
SAA1.1KO mice (containing only the SAA2.1 isoform), and 
SAA2.1KO mice received HDL prepared from SAA2.1KO 
mice (containing only the SAA1.1 isoform). Clearance 
rates for the two SAA isoforms were not significantly differ-
ent (FCR for SAA1.1 = 0.26 ± 0.02/h; SAA2.1 = 0.23 ± 
0.03/h) (Fig. 6; Table 2, section B). The clearance rates of 
apoA-I and apoA-II were also not significantly different 
when compared in the two single KO strains. There was an 
apparent increase in the initial rate of clearance of SAA1.1 
compared with SAA2.1, consistent with an increased fast 
phase rate constant (1.6-fold) compared with SAA2.1 clear-
ance (Kfast SAA1.1 = 1.08 ± 0.07/h vs. SAA2.1 = 0.66 ± 
0.07/h; P = 0.0025). Similar to SAA1.1, the fast phase rate 
constant of apoA-II was increased in the SAA2.1KO HDL 
compared with SAA1.1KO HDL (Kfast apoA-II = 0.98 ± 
0.16 vs. apoA-II = 0.47 ± 0.06/h, respectively; P = 0.02). 
Together, these results show that the two AP SAA isoforms 
are cleared at similar rates from AP-HDL under AP condi-
tions, although a difference in the initial fast clearance 
phase between the two SAA isoforms was observed.
The role of SR-BI in clearance of HDL apolipoproteins
The scavenger receptor, SR-BI, plays a key role in the 
metabolism of HDL (48). SR-BI binds HDL through its 
high-affinity interaction with the apolipoproteins of HDL, 
including SAA (49), and mediates the selective lipid up-
take of CEs into cells without requiring the endocytic up-
take of intact HDL particles. In previous studies, we 
showed that SR-BI mediates cellular uptake of SAA from 
HDL at a much greater rate than apoA-I, suggesting that 
SR-BI may contribute to the plasma clearance of SAA (49). 
Table 2, section A). apoA-II (FCR = 0.11 ± 0.01/h) cleared 
at an intermediate rate, which was significantly different 
from both apoA-I and SAA clearance rates. When AP-HDL 
clearance was analyzed in normal mice, SAA was again 
cleared more rapidly than apoA-I and apoA-II. Interest-
ingly, whereas the clearance rate of apoA-I in AP-HDL was 
similar in normal and AP mice, the FCRs of both SAA and 
apoA-II in AP-HDL were more rapid in normal than in AP 
mice, although these differences did not reach signifi-
cance. The rapid initial phase of clearance for both SAA 
and apoA-II from AP-HDL was also faster in normal mice 
than in AP mice. This was consistent with an observed in-
crease in the fast phase rate constant (Kfast) for SAA in 
normal compared with AP mice (Kfast = 1.3 ± 0.24/h vs. 
0.79 ± 0.14/h, respectively), although this difference did not 
reach significance.
The clearance rates of the apolipoproteins in N-HDL 
were also compared in normal and AP mice (Fig. 5; Table 2, 
TABLE 1. Composition of N- and AP-HDL from WT, SAA1.1KO, and SAA2.1KO mice
WT Saline (%) WT LPS (%)
SAA1.1KO  
Saline (%) SAA1.1KO LPS (%)
SAA2.1KO  
Saline (%) SAA2.1KO LPS (%)
Protein 47.7 ± 1.40 44.9 ± 1.24 48.4 ± 1.71 48.1 ± 2.73 48.3 ± 1.89 46.5 ± 3.16
FC 4.1 ± 0.12 6.9 ± 0.59a 3.7 ± 0.44 7.1 ± 0.69a 4.1 ± 0.24 7.7 ± 0.51a
CE 15.2 ± 0.36 12.3 ± 1.39a 14.5 ± 1.12 9.0 ± 1.83a 15.0 ± 0.74 9.7 ± 0.66a
TGs 1.3 ± 0.52 1.5 ± 0.58 1.8 ± 0.65 1.5 ± 0.41 0.8 ± 0.09 1.1 ± 0.20
PLs 31.7 ± 1.33 34.4 ± 1.05 31.3 ± 2.72 34.3 ± 2.10 31.8 ± 2.07 34.9 ± 2.34
Values are the mean ± SEM of three HDL preparations for each group. CE was calculated as the difference 
between TC and FC.
aP < 0.001 for LPS-injected mice versus saline-injected mice.
Fig. 4. ABCG1-mediated cholesterol efflux to AP WT HDL, 
SAA1.1KO HDL, SAA2.1KO HDL, and SAAKO HDL. Transfected 
BHK cells were labeled with [3H]cholesterol and then induced to 
express ABCG1 as described in the Materials and Methods. Cellu-
lar cholesterol efflux was measured during a 5 h incubation with 25 
g/ml AP WT HDL (white bars), AP SAA1.1KO HDL (light gray 
bars), AP SAA2.1KO HDL (dark gray bars), or AP SAAKO HDL 
(black bars). ABCG1-dependent efflux represents the difference 
between BHK cells treated with mifepristone (Total) and untreated 
cells (ABCG1-independent). The data shown are representative of 
three experiments each performed in triplicate. Values are the 
mean ± SEM. *P < 0.05, **P < 0.01, ***P < 0.001.
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SAA’s rapid clearance compared with apoA-I and apoA-II 
is not in large part dependent on SR-BI.
DISCUSSION
To better understand the metabolism of the AP SAA iso-
forms and their impact on HDL size, composition, and 
catabolism, we generated mice that lacked either SAA1.1 
or SAA2.1. With respect to isoform gene expression, there 
was a lower abundance of SAA1.1 mRNA in the liver com-
pared with SAA2.1 mRNA in the respective SAAKO mice, 
suggesting that while the two genes were coordinately reg-
ulated, either their rate of transcription or the stability of 
their two mRNAs differed. Plasma SAA levels were lower in 
both single KO mice compared with WT mice, indicating 
that, in the AP, the absence of one SAA isoform does not 
lead to a significant compensatory increase in the expres-
sion of the other isoform. Furthermore, the capacity of 
liver cells to transcribe, translate, and secrete one AP iso-
form is apparently not limited by the expression of the 
other isoform.
Infection and inflammation affect plasma lipids differ-
ently in different species. In humans and nonhuman pri-
mates, plasma TC typically declines during the AP (44, 53). 
In contrast, in rodents, plasma cholesterol increases dur-
ing an AP response due to increased de novo cholesterol 
synthesis, reduced lipoprotein clearance, and a reduction 
To investigate the possible role of SR-BI in the rapid clear-
ance of SAA, we studied the rate of SAA clearance in mice 
lacking SR-BI.
Because SRBI/ mice have high levels of abnormally 
large HDL that has an altered lipid and apolipoprotein 
composition, clearance was examined in CETPtg mice and 
CETPtg mice crossed with SR-BI/ mice. The expression 
of CETP in SRBI/ mice results in the normalization of 
the size and plasma concentration of HDL (50), thereby 
providing a model for analyzing the role of SR-BI in the 
clearance of SAA from AP-HDL. For simplicity, the CETPtg 
mice are referred to as WT mice and CETPtg mice crossed 
with SR-BI/ mice as SR-BIKO mice. The recipient mice 
in this experiment were not preinjected with LPS because 
we have previously shown SRBI/ mice to be extremely 
sensitive to LPS (51). 125I-AP-HDL was injected into WT 
mice or SR-BIKO mice. As shown in Fig. 7 and Table 2, 
section C, the clearance rate of SAA in SR-BIKO mice was 
reduced (approximately 30%) compared with the clear-
ance rate in WT mice (FCR = 0.39 ± 0.05/h and FCR = 0.57 ± 
0.03/h, respectively; P < 0.05). In contrast, the clearance 
rates of apoA-I and apoA-II were not significantly altered 
by the absence of SR-BI in the SR-BIKO mice, consistent 
with previous findings that plasma levels of apoA-I were 
similar in WT and SR-BI/ mice and the known function 
of SR-BI in mediating HDL-CE uptake selectively, without 
the uptake of HDL protein (52). These results indicate 
that although SR-BI may influence the clearance of SAA, 
Fig. 5. Plasma clearance of apoA-I, apoA-II, and SAA from AP-HDL and N-HDL. 125I-labeled AP-HDL or 125I-N-HDL (30 g) was intrave-
nously administered to normal mice (N mice) or mice 24 h after injection of LPS (1 g/g) (AP mice). Blood samples were collected at 
selected times up to 24 h after HDL administration and processed as set out in the Materials and Methods. Radioactivity at each time point 
is expressed as a percentage of the radioactivity at 3 min. Data were plotted with GraphPad Prism 4 as described in the Materials and Meth-
ods. The y axis represents radioactivity associated with apoA-I, apoA-II, and SAA proteins isolated by gel electrophoresis. Values plotted are 
mean ± SE, n = 5 mice.
TABLE 2. FCRs
Experiment SAA FCR per Hour ApoA-I FCR per Hour ApoA-II FCR per Hour
A AP-HDL → AP mice 0.22 ± 0.03 0.062 ± 0.006 0.11 ± 0.01
AP-HDL → N mice 0.31 ± 0.03 0.072 ± 0.005 0.14 ± 0.01
N-HDL → N mice — 0.071 ± 0.004 0.14 ± 0.01
B SAA1.1KO mice (SAA2.1) 0.23 ± 0.03 0.093 ± 0.007 0.14 ± 0.01
SAA2.1KO mice (SAA1.1) 0.26 ± 0.02 0.077 ± 0.008 0.18 ± 0.01
C AP-HDL → WT micea 0.57 ± 0.03b 0.076 ± 0.003 0.12 ± 0.005
AP-HDL → SR-BIKO micea 0.39 ± 0.05 0.066 ± 0.002 0.14 ± 0.01
Values are the mean ± SE. For intra-experimental comparisons, differences between FCRs for SAA, apoA-I, and 
apoA-II were highly significant (P < 0.01). N mice, normal mice.
a Mice on a CETPtg background.
bP < 0.05 for FCR of SAA in WT mice versus SR-BIKO mice.
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on AP-HDL from WT mice was offset by a reduction in 
apoA-I content, whereas apoA-II content did not vary sig-
nificantly between normal and AP-HDLs (14). In the single 
SAAKO mice, the reduction in apoA-I content of AP-HDL 
to compensate for SAA was less evident, likely due to the 
fact that AP-HDLs from both single KO mice contained 
less SAA than AP-HDL from WT mice. Nondenaturing gel 
electrophoresis showed that SAA-containing AP-HDL 
from both SAA1.1KO and SAA2.1KO mice migrates as 
larger than normal particles, similar in size to AP-HDL 
from WT mice. The increased size of AP-HDL compared 
with N-HDL (3) has been attributed to the hydrophilic C-
terminal end of SAA extending beyond the surface of the 
HDL particle (55). However, the fact that AP-HDLs from 
SAA-depleted mice also migrate as larger particles, indi-
cates that changes other than SAA content are responsible 
for the increased size of AP-HDL (14).
Studies have indicated the two major SAA isoforms may 
have different metabolic fates and functions. In humans, 
the SAA1.1 isoform is preferentially deposited in amyloid 
fibrils (28), with some allelic variants being more amyloido-
genic than others (56). Similarly, SAA1.1 is the predomi-
nant form in amyloid fibrils in mice (56). SAA isoforms 
have been reported to exhibit functional differences in 
their ability to affect cellular cholesterol efflux. SAA2.1, 
but not SAA1.1, was shown to both suppress ACAT in cells 
and to stimulate cholesterol esterase, effects that would be 
expected to promote cholesterol efflux (57). In the pres-
ent study, we investigated whether the ability of HDL to 
promote efflux was differentially affected by SAA1.1 and 
SAA2.1. ABCG1-mediated cholesterol efflux was exam-
ined because HDL is the preferred cholesterol acceptor 
for this cholesterol transporter. Our results failed to show 
any significant difference between the two isoforms in 
their ability to promote or otherwise affect efflux. It re-
mains possible that the isoforms may exert effects on efflux 
that are not detected in our assays. These might include 
effects that are independent of ABCG1 or elicited by 
lipid-poor SAA that is not associated with HDL, or by cell 
signaling events that are not elicited in our cell culture 
assay system.
in conversion of cholesterol to bile acids (44, 45). In the 
present study, although there was increased plasma cho-
lesterol in WT, SAA1.1KO, and SAA2.1 female mice in the 
AP, there was actually a decrease in male mice, regardless 
of genotype. The observed gender effect is not under-
stood. Like total plasma cholesterol, HDL cholesterol 
levels in the AP decline dramatically in humans (42) and 
nonhuman primates (44), as well as in rodents as reported 
in some (54), but not all (14, 44), studies. In this study, 
HDL cholesterol levels in both genders were similar in WT 
and the two single KO mice under normal conditions and 
were significantly reduced in the AP, although the reduction 
in the AP was more pronounced in male mice, which had 
higher HDL levels under normal conditions than female 
mice. Again, the observed effect of gender is unexplained.
The HDLs isolated from SAA1.1KO and SAA2.1KO 
mice exhibited expected changes in apolipoprotein com-
position. We reported previously that the presence of SAA 
Fig. 6. Plasma clearance of SAA1.1 and SAA2.1 from AP-HDL. 125I-labeled AP-HDLs (30 g) containing either SAA1.1 or SAA2.1, ob-
tained from SAA2.1KO or SAA1.1KO mice, were intravenously administered to autologous mice 24 h after injection of LPS (1 g/g). Blood 
samples were collected at selected times up to 24 h after HDL administration and processed as set out in the Materials and Methods. Ra-
dioactivity at each time point is expressed as a percentage of the radioactivity at 3 min. Data were plotted with GraphPad Prism 4 as de-
scribed in the Materials and Methods. The y axis represents radioactivity associated with apoA-I, apoA-II, and SAA isoforms isolated by gel 
electrophoresis. Values plotted are mean ± SE, n = 5 mice.
Fig. 7. Plasma clearance of SAA from AP-HDL in WT and SRBIKO 
mice. 125I-labeled AP-HDL (30 g) was intravenously administered 
to CETPtg (WT) and CETPtg mice lacking SR-BI (SRBIKO mice). 
Blood samples were collected at selected times up to 24 h after 
HDL administration and processed as set out in the Materials and 
Methods. Radioactivity at each time point is expressed as a percent-
age of the radioactivity at 3 min. Data were plotted with GraphPad 
Prism 4 as described in the Materials and Methods. Values are 
mean ± SE, n = 5 mice.
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splenic tissue. Because the production and secretion of 
the two isoforms appeared to be similar in these mice, the 
data suggested that the selective loss of plasma SAA1.1 in-
volved a selective and accelerated removal of the isoform 
from plasma, although plasma clearance rates were not 
directly measured. It is possible that the rate of SAA1.1 
clearance is selectively altered under the conditions that 
lead to its selective deposition in casein-induced amyloid 
and that such conditions are not mimicked in the AP 
model used in the present study.
A possible role of SR-BI as a candidate receptor involved 
in SAA plasma clearance was examined. We (49) and oth-
ers (61) showed that SR-BI is a high-affinity receptor for 
SAA that internalizes SAA at a markedly greater rate than 
apoA-I (49). Clearance was examined in control and SR-
BI/ mice that both overexpressed CETP. The plasma 
expression of CETP in SR-BI/ mice normalizes the size 
and plasma concentration of HDL, thereby providing a 
model for analyzing the role of SR-BI in the clearance of 
SAA from AP-HDL (50). Our results show that the plasma 
clearance rates of apoA-I and apoA-II are not significantly 
altered in mice lacking SR-BI. In contrast, SAA clearance 
was significantly reduced (about 30%) in SR-BIKO mice. 
Although significant, this contribution of SR-BI to SAA 
clearance cannot account for the considerably faster 
plasma clearance rate (4-fold) of SAA compared with 
apoA-I. It is possible that SR-BI plays a role in mediating 
SAA uptake into cells, such as hepatocytes, but the rates of 
such uptake are evidently too low to markedly affect total 
plasma clearance rates.
The mechanisms responsible for the differential rates 
of removal of the different HDL apolipoproteins are 
poorly understood. In the case of apoA-I, clearance occurs 
mainly in the kidney and liver. Lipid-free/lipid-poor 
apoA-I particles are the preferred substrate for apoA-I up-
take into the kidney (62), where it is filtered and then ab-
sorbed in kidney proximal tubules through the action of 
cubilin, a receptor for intrinsic factor-vitamin B12, with 
megalin serving as a coreceptor (63–65). A number of 
HDL-modifying processes can potentially generate small 
lipid-free/lipid-poor apoA-I particles. These include HDL 
remodeling within plasma, for example, through the ac-
tions or combined actions of CETP, hepatic and endothe-
lial lipase, and SR-BI (15, 66, 67). Like apoA-I, apoA-II is 
also cleared through the kidney and can be reabsorbed 
through cubilin/megalin receptors. As shown in our study, 
apoA-II in mice is cleared more rapidly from plasma than 
apoA-I, but the reason(s) for this is unknown. Unfortunately, 
the biological identities of the slow and fast phases of clear-
ance of apoA-II as well as SAA are not understood and the 
pathway(s) responsible for the relatively rapid plasma 
clearance of SAA remain undefined. Like apoA-II (68), 
SAA is more hydrophobic than apoA-I, binds strongly to 
HDL, and can displace apoA-I from HDL, at least in vitro 
(3, 69). The fact that the presence of SAA on AP-HDL does 
not alter the rate of apoA-I clearance suggests that SAA 
might not affect those processes that generate the lipid-
free/lipid-poor apoA-I particles that serve as substrates for 
plasma apoA-I clearance.
The current studies examined the plasma clearance rates 
of SAA and its two predominant isoforms, as well the effect 
of SAA on the plasma clearance of apoA-I and apoA-II. Re-
sults showed that SAA on HDL is cleared more rapidly 
from plasma than apoA-I, confirming previous findings 
carried out in mice (30, 58) and monkeys (32, 33). apoA-II 
was shown to have an intermediate FCR. The distinct FCRs 
of the three apolipoproteins support the notion that nei-
ther normal nor AP-HDL particles are cleared as intact 
particles, but rather through mechanisms that involve 
dissociation of apolipoproteins from HDL. The FCRs of 
apoA-I from normal and AP-HDLs were similar when mea-
sured in normal mice, suggesting that the presence of SAA 
on AP-HDL does not influence the clearance of apoA-I. 
This finding is consistent with the recent report that the 
displacement of an exchangeable fraction of apoA-I by 
SAA has only a minor effect on the structural stability of 
HDL particles (59). Similarly, the clearance rates of apoA-
II in N-HDL and AP-HDL did not differ when measured in 
normal mice. When clearance of the AP-HDL was carried 
out in AP mice, clearance rates for both SAA and apoA-II, 
but not for apoA-I, were decreased compared with clear-
ance rates in normal mice. The explanation for the selec-
tive negative impact of the AP on SAA and apoA-II plasma 
clearance is unclear. It is possible that AP-HDL has under-
gone remodeling in acute plasma that affects the turnover 
of some, but not all, apolipoproteins. Alternatively, the 
apolipoprotein clearance pathways in the normal and AP 
mice may differ.
To compare the turnover rates of SAA1.1 and SAA2.1, 
we isolated AP-HDL from SAA2.1KO and SAA1.1KO mice, 
respectively. This allowed us to study native AP-HDLs 
rather than HDLs that had undergone any type of recon-
stitution procedure necessitated by having to label specific 
apolipoproteins. FCRs were determined by injecting ra-
diolabeled AP-HDL from SAA1.1KO or SAA2.1KO mice 
into syngeneic AP mice. Importantly, no significant differ-
ence was found between the FCRs of SAA1.1 and SAA2.1. 
We did, however, observe that SAA1.1 was cleared more 
rapidly by the fast phase component. A previous study, 
which examined mouse recombinant SAA isoforms that 
were reconstituted in normal or AP mouse HDL, also re-
ported that SAA1.1 (previously termed SAA2) was more 
rapidly cleared than SAA2.1 (previously termed SAA1) in 
BALB/c mice, although only apparent half-life values and 
not FCR values were determined (31). However, the dif-
ference between the isoforms was only observed when 
clearance was measured either from reconstituted N-HDL 
or from AP-HDL analyzed in nonacute phase mice. Simi-
larly, no significant difference was reported between the 
clearance rates of SAA1 and SAA2 in the AP in nonhuman 
primates (32). The similar rates of plasma clearance of the 
two SAA isoforms in AP mice suggest that the selective de-
position of SAA1.1 in amyloid plaques (27) may not im-
pact its rate of plasma clearance or reflect an increased 
clearance from HDL. In a previous study, Meek and Ben-
ditt (60) showed that plasma levels of SAA1.1 decline se-
lectively compared with SAA2.1 in a casein-induced AP 
mouse model in which SAA1.1 is selectively deposited in 
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Unlike the small, but important, fraction of apoA-I that 
exists in plasma as lipid-poor apoA-I or small lipid-poor 
pre-HDL particles, SAA is found largely bound to lipo-
proteins, predominantly HDL. The mechanisms responsi-
ble for selective SAA dissociation or segregation from bulk 
HDL and the other major HDL apolipoproteins prior to 
SAA clearance are not understood. It should be noted that 
the present study examines the clearance rate of SAA that 
is present in mature HDL particles. It is possible that a 
fraction of SAA may be rapidly cleared from plasma before 
becoming part of mature HDL particles. Such a pathway 
would not be detected or quantified in our studies. The 
liver and kidney appear to be the major sites of SAA clear-
ance in mice, although the rates of SAA tissue uptake have 
not been directly quantified (30). Aside from its uptake 
into liver, kidney, and other cell types, another process 
that might contribute to rapid plasma SAA clearance is the 
known ability of SAA to bind to cell-associated proteogly-
cans, including perlecan, located on epithelial cells in the 
circulatory system (70). It is possible that the initial rapid 
clearance phase of SAA is due, at least in part, to the bind-
ing of SAA to proteoglycans. The observation that SAA 
clears more slowly in AP mice than in normal mice may be 
the result of endogenous SAA saturating SAA proteogly-
can binding sites.
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